Clinical trials: Dermatitis Atopic
Atopic Dermatitis
Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis
Various clinical studies have evaluated the role of probiotics in children with atopic dermatitis, with some studies showing improvement in clinical outcome after supplementation of probiotics and others showing no additional…
- Trial name
- NCT04706559
- Testing
- Probiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii, Conventional treatment
- Where
- Nepal
- Volunteers
- 98 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
Dermatitis, Atopic
A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis
The objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.
- Trial name
- NCT03096223
- Testing
- KHK4083
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Seasonal Allergic Rhinitis, Allergic Conjunctivitis
Montelukast as a Controller of Atopic Syndrome
The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.
- Conditions
- Seasonal Allergic Rhinitis, Allergic Conjunctivitis, Atopic Eczema, Asthma
- Trial name
- MONTAS (NCT00559546)
- Testing
- montelukast
- Where
- Finland
- Volunteers
- 61 people
- Sponsor
- University of Helsinki
Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
This is a 6-part first-in-human study in up to approximately 184 participants. Parts 1 to 5 is in health volunteers and part 6 is in subjects with atopic dermatitis.
- Trial name
- NCT03918980
- Testing
- LOU064
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD.
- Trial name
- NCT05571943
- Testing
- Difamilast
- Where
- 63 sites in United States
- Volunteers
- 542 people
- Sponsor
- Acrotech Biopharma Inc.
Atopic Dermatitis, Pruritus
Management of Pruritus With Xyzal in Atopic Dermatitis
It is historically well known that the management of pruritus in atopic dermatitis is very difficult. Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra.
- Trial name
- NCT00884325
- Testing
- Levocetirizine dihydrochloride (Xyzal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Derm Research, PLLC
Atopic Dermatitis
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01639040
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 31 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects
The goal of this two-sequence, two-cycle, single and multiple-dose Phase I clinical trial is To evaluate the human bioequivalence of the test preparation and the reference preparation in 28 healthy chinese subjects at a single…
- Trial name
- NCT05945810
- Testing
- TLL-018 extended-release tablet, TLL-018 immediate-release tablet
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis (AD)
Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults
Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD.
- Trial name
- NCT07276620
- Testing
- Ivarmacitinib Sulfate Tablets
- Volunteers
- 1,000 people
- Sponsor
- Xiangya Hospital of Central South University
Atopic Dermatitis
A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for…
- Trial name
- Rising Up (NCT03661138)
- Testing
- Upadacitinib, Topical Corticosteroids (TCS)
- Where
- 43 sites in Japan
- Volunteers
- 272 people
- Sponsor
- AbbVie
Atopic Dermatitis, Alopecia Areata
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)).
- Trial name
- NCT07242638
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Atopic Dermatitis
CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for patients with atopic dermatitis under the care of a licensed…
- Trial name
- NCT04504955
- Testing
- Observational Non-Interventional Registry
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- CorEvitas
Atopic Dermatitis
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with…
- Trial name
- ATLAS (NCT05155085)
- Testing
- AK002
- Where
- 55 sites in United States, Germany
- Volunteers
- 131 people
- Sponsor
- Allakos Inc.
Microbiota, Eczema
Intestinal Microbiota Composition After Antibiotic Treatment in Early Life
In this prospective observational cohort study the potential clinical consequences of antibiotic use in early life and perturbations in the gastrointestinal microbiota composition due to that antibiotic use are studied.
- Conditions
- Microbiota, Eczema, Atopy
- Trial name
- INCA (NCT02536560)
- Where
- 4 sites in Netherlands
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Agentschap NL
Psoriasis, Atopic Dermatitis
Involvement of Pollutants in Atopic Dermatitis and Psoriasis
Introduction Pollution is a significant public health issue. Research has shown a positive correlation between air pollution and chronic inflammatory dermatoses, including psoriasis and eczema.
- Trial name
- DIAhR (NCT06213688)
- Testing
- blood sampling, urine sampling
- Volunteers
- 64 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Atopic Dermatitis
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis
The purpose of the study is to explore the efficacy and safety of SUN13834 vs placebo in adult participants with atopic dermatitis.
- Trial name
- NCT00717769
- Testing
- SUN13834
- Where
- 28 sites in United States
- Volunteers
- 270 people
- Sponsor
- Daiichi Sankyo
Atopic Dermatitis
A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.
- Trial name
- NCT05579925
- Testing
- CM310
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis (AD)
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
- Trial name
- COMPASS 2-AD (NCT07105488)
- Testing
- BFB759
- Where
- 88 sites in United States, Bulgaria and 5 more
- Volunteers
- 225 people
- Sponsor
- Bluefin Biomedicine, Inc.
Atopic Dermatitis Eczema
Study in Subjects With Moderate Atopic Dermatitis
This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in…
- Trial name
- NCT03859986
- Testing
- ALX-101 Gel Vehicle, ALX-101 Gel 5%
- Where
- 22 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- Ralexar Therapeutics, Inc.
Atopic Dermatitis
Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week
- Trial name
- NCT06026891
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.